The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials by Thinzar, Min & Steve, Bain
REVIEW
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor
Agonist, in the Management of Type2 Diabetes: The
SURPASS Clinical Trials
Thinzar Min . Stephen C. Bain
Received: October 27, 2020 /Accepted: November 28, 2020
 The Author(s) 2020
ABSTRACT
Glucagon-like peptide 1 (GLP-1) based therapy
is an established treatment option for the
management of type 2 diabetes mellitus
(T2DM) and is recommended early in the
treatment algorithm owing to glycaemic effi-
cacy, weight reduction and favourable cardio-
vascular outcomes. Glucose-dependent
insulinotropic polypeptide (GIP), on the other
hand, was thought to have no potential as a
glucose-lowering therapy because of observa-
tions showing no insulinotropic effect from
supraphysiological infusion in people with
T2DM. However, emerging evidence has illus-
trated that co-infusion of GLP-1 and GIP has a
synergetic effect, resulting in significantly
increased insulin response and glucagonostatic
response, compared with separate administra-
tion of each hormone. These observations have
led to the development of a dual GIP/GLP-1
receptor agonist, known as a ‘twincretin’. Tir-
zepatide is a novel dual GIP/GLP-1 receptor
agonist formulated as a synthetic peptide con-
taining 39 amino acids, based on the native GIP
sequence. Pre-clinical trials and phase 1 and 2
clinical trials indicate that tirzepatide has
potent glucose lowering and weight loss with
adverse effects comparable to those of estab-
lished GLP-1 receptor agonists. The long-term
efficacy, safety and cardiovascular outcomes of
tirzepatide will be investigated in the SURPASS
phase 3 clinical trial programme. In this paper,
we will review the pre-clinical and phase 1 and 2
trials for tirzepatide in the management of
T2DM and give an overview of the SURPASS
clinical trials.
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Tirzepatide is a dual GIP/GLP-1 receptor
agonist (RA) formulated as a synthetic
linear peptide containing 39 amino acids,
based on the native GIP sequence.
Tirzepatide is administered
subcutaneously once weekly because of its
half-life of 5 days.
In the phase 1 and phase 2 trials
tirzepatide demonstrated dose-dependent
reduction in HbA1c (up to 2.4%) and body
weight (up to 11.3 kg) in patients with
T2DM.
The clinical efficacy of tirzepatide is
superior to the GLP-1 RA dulaglutide.
Most common adverse effects are related
to the gastrointestinal tract and
comparable to the GLP-1 RA dulaglutide.
There are nine ongoing SURPASS clinical
trials investigating the efficacy and safety
of tirzepatide in individuals with T2DM
on various glucose-lowering therapies.
The SURPASS-CVOT is a large phase 3,
randomised, double-blind, cardiovascular
outcomes trial for tirzepatide assessing
both non-inferiority and superiority of
tirzepatide against dulaglutide (1.5 mg
weekly).
DIGITAL FEATURES
This article is published with digital features to
facilitate understanding of the article. You can
access the digital features on the article’s asso-
ciated Figshare page. To view digital features for
this article go to https://doi.org/10.6084/m9.
figshare.13293128.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic
progressive disease associated with microvascu-
lar and macrovascular complications and
increased cardiovascular mortality. The patho-
genesis of T2DM is a complex process and yet to
be fully understood. A combination of insulin
resistance (in the early phase of the disease
process) and relative insulin deficiency results
in hyperglycaemia. Chronic hyperglycaemia
leads to glucose toxicity, which in turn causes
pancreatic beta cell dysfunction and exacerbates
insulin deficiency in the late phase. The ulti-
mate result of this is a viscous cycle of hyper-
glycaemia leading to a worsening metabolic
state. One of the main modifiable risk factors for
diabetes is obesity. The parallel rise in the
prevalence of obesity and T2DM (known as
‘diabesity’) is a global health challenge. Obesity
is strongly associated with insulin resistance,
one of the key features in pathogenesis of T2DM
and one of the barriers for achieving good gly-
caemic control. Management of T2DM, there-
fore, includes dietary intervention and lifestyle
modification to promote weight loss along with
pharmacotherapy to combat hyperglycaemia
and optimise metabolic parameters such as
blood pressure and lipids, and metabolic surgery
in some cases.
The ideal glucose-lowering medication
should be efficacious, not associated with
weight gain (but promoting weight loss), have
low risk of hypoglycaemia and proven cardio-
vascular benefits. The last 15 years or so have
seen new classes of diabetes medications avail-
able for management of T2DM: glucagon-like
peptide 1 (GLP-1) receptor agonists (exenatide
being the first, approved by the US Food and
Drug Administration [FDA] in 2005), dipeptidyl
peptidase 4 (DPP4) inhibitors (sitagliptin, first
DPP4i, approved in 2006) and sodium–glucose
co-transporter 2 (SGLT2) inhibitors (canagli-
flozin [USA] and dapagliflozin [EU] in 2012 and
2013 respectively). These newer glucose-lower-
ing drugs are effective (HbA1c reduction
1.5–1.8% with once weekly semaglutide 1 mg)
and promote weight loss (4.5–6.5 kg loss with
once weekly semaglutide 1 mg) [1]. Despite
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these advances in therapy, there are a signifi-
cant proportion of people with T2DM who do
not achieve optimal glycaemic control. As per
the National Diabetes Audit data, only 65.9% of
people with T2DM in England and Wales
achieved the recommended
HbA1c\ 58 mmol/mol (7.5%) [2]. The NDA
data also showed that 85% of people with
T2DM were overweight or obese. Therefore,
there is a drive for the development of glucose-
lowering medications which are not only
effective in reduction of HbA1c but also in
promoting substantial weight loss.
This article is based on previously conducted
studies and does not contain any new studies
with human participants or animals performed
by any of the authors.
PHYSIOLOGY OF INCRETIN
HORMONES
The term ‘incretin’, first described in 1932,
refers to hormones released from the gut that
regulate the insulin response to a meal [3]. The
seminal paper by Elrick et al., published in
1964, demonstrated a significant and sustained
rise in plasma insulin response following an oral
glucose load, compared to a parental glucose
load [4]. This phenomenon was later known as
‘the incretin effect’ and this accounts for up to
65% of postprandial insulin secretion [5, 6].
There are two principal incretin hormones
responsible for the incretin effect: glucagon-like
peptide 1 (GLP-1) and glucose-dependent insu-
linotropic polypeptide (GIP, formerly known as
gastric inhibitory polypeptide) (Table 1) [7].
GLP-1 is a 30 amino acid peptide, synthe-
sised in the L cells of the intestine. Once
released into the circulation, GLP-1 binds to a
specific GLP-1 receptor, which is expressed in
the pancreas, gastrointestinal tract, kidney,
heart and brain [7]. Endogenous GLP-1 has a
short half-life of 1–2 min and is metabolised by
the enzyme DPP4. In additional to the well-
known insulinotropic property in response to
nutrients in the gut, GLP-1 has a glucagonos-
tatic effect, inhibiting glucagon secretion in the
hyperglycaemic and normoglycaemic state but
not during hypoglycaemia. Extrapancreatic
properties of GLP-1 include slowing of gastric
emptying, promoting satiety and reducing food
intake [8].
Table 1 Functions of GLP-1 and GIP in glucose and energy metabolism
GLP-1 GIP

















GIP is a 4 amino acid peptide, produced by
the K cells of the intestine, mainly located in
the duodenum and proximal jejunum. GIP is
released in response to oral nutrients, especially
carbohydrates and lipids. GIP, like GLP-1, has a
short half-life (4–7 min) and is inactivated by
DPP4, shortly after release. GIP receptors are
present in various tissues such as the pancreas,
adipose tissue, gastric mucosa, heart, adrenal
cortex, bone and brain [7]. Endogenous GIP also
stimulates glucose-dependent insulin secretion
and is responsible for a greater proportion of the
incretin effect than GLP-1 [9, 10]. One differ-
ence between GIP and GLP-1 is the effect on
glucagon secretion. Unlike GLP-1, GIP has dual
functions: a glucagonotropic property in the
normoglycaemic and hypoglycaemic state, and
glucagonostatic in the hyperglycaemic state
[11]. The effect of GIP on adipose tissue and
body weight regulation has yet to be estab-
lished. Some studies reported that GIP receptor
knockout mice, unlike control mice, were
resistant to diet-induced obesity [12], suggesting
the adipogenic effect, whereas other studies
demonstrated that chronic elevation of GIP
concentrations in a transgenic mouse reduced
diet-induced obesity and promoted insulin
sensitivity, glucose tolerance and beta cell
function [13]. Since GIP is found to have glu-
cagonotropic properties, the other hypothetical
mechanism for GIP-induced weight loss is





The incretin effect is significantly reduced in
patients with T2DM, compared to people with-
out diabetes [7]. The proposed mechanisms
behind the loss of incretin effect include (1) a
reduction in incretin hormone response to
nutrients (hyposecretion) and (2) a reduction in
insulinotropic effect on pancreatic beta cells.
Early studies showed that there was hyposecre-
tion of GLP-1 in people with T2DM [14, 15], but
emerging evidence does not support this
observation [16]. In fact, reduction in
insulinotropic effect of GLP-1 was observed in
patients with T2DM [17] and supraphysiological
doses of GLP-1 receptor agonists were found to
partly restore the incretin effect. This has led to
the development of widely available GLP-1-
based therapy for management of T2DM.
With respect to GIP secretion, there are
consistent reports demonstrating no reduction
in GIP secretion in people with T2DM [18–20].
However, GIP resistance, a complete loss of
insulinotropic effect of GIP at physiological
concentrations as well as supraphysiological
concentrations was observed in people with
T2DM [17, 21]. In addition, some studies found
that the glucagonotropic effect of GIP persists
even in the hyperglycaemic state [22]. These
observations in the past have made GIP
unattractive as a therapeutic agent for T2DM.
However, emerging evidence suggests that GIP
resistance can be modified and restored by
improving glycaemic control. GIP receptors on
pancreatic beta cells are downregulated owing
to chronic hyperglycaemia, resulting in subse-
quent loss of insulinotropic effect. In a study by
Hojberg et al., GIP administration increased
insulin response, partly restoring insulinotropic
properties in eight people with T2DM whose
glycaemic control was optimised by using
4-week insulin therapy [23]. A potential addi-
tional benefit of GIP is safeguarding against
hypoglycaemia. GIP infusion was associated
with lower glucose infusion requirement to
maintain a desired level of blood glucose during
an insulin-induced hypoglycaemic clamp [24].
The evidence mentioned above has paved the
way to development of GIP receptor agonist-
based therapy for T2DM.
DUAL GIP AND GLP-1 AGONISM
Co-administration of GIP and a GLP-1 receptor
agonist (RA) in healthy individuals has a additive
effect, generating a significantly increased insulin
response compared with separate administration
of each hormone [9, 25]. Furthermore, the com-
bined infusion produced a significant
glucagonostatic effect while separate administra-
tion of GIP or GLP-1 did not suppress glucagon
secretionmore than glucose alone [25]. However,
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in people with T2DM, co-administration of GIP
and GLP-1 over a short period of time (4–6 h) did
not generate an insulin response greater than that
of GLP-1 administration alone [26–28].
The long-term effect of GIP and GLP-1 recep-
tor agonism was first described by Finan et al.
who developed a unimolecular dual agonist of
GIP and GLP-1 receptors, referred to as a ‘twin-
cretin’ [29]. The twincretin was shown to have
high affinity to GLP-1 and GIP receptors with
negligible glucagon receptor activity. In animal
studies, GIP and GLP-1 receptor co-agonist ther-
apy at 1–3 weeks produced a dose-dependent
reduction in blood glucose, body weight, food
intake and fat mass compared to placebo,
equimolar dose of exendin-4 or liraglutide. The
co-agonist can be modified by attaching a poly-
ethylene glycol (PEG) or a 16-carbon acyl chain
to extend half-life (allowing weekly dosing). The
PEGylated co-agonist was investigated in 44
people with T2DM. After 6 weeks, a dose-depen-
dent decrease inHbA1c compared to placebowas
observed. The co-agonist was well tolerated with
mild to moderate GI side effects and no hypo-
glycaemic events [29].
TIRZEPATIDE
Tirzepatide (LY3298176) developedbyEli Lilly is a
dual GIP/GLP-1 receptor agonist formulated as a
synthetic linear peptide containing 39 amino
acids, based on the native GIP sequence. It is
attached to a 20-carbon fatty diacid moiety,
whichbinds toalbumin,prolonging itshalf-life to
5 days and thus enabling once weekly dosing.
Tirzepatide has a comparable GIP receptor bind-
ingaffinity tonativeGIPandfive times lowerGLP-
1 receptor affinity than that of native GLP-1 [30].
Similar to the GLP-1 RA tirzepatide is adminis-
tered subcutaneously. The clinical efficacy, safety
and tolerabilityof tirzepatidehas been reported in
phase 1 and phase 2 clinical trials (Table 2).
EFFICACY OF TIRZEPATIDE
IN PHASE 1 CLINICAL TRIALS
A phase 1 proof-of-concept clinical trial was
conducted in 53 people with T2DM, comprising
five groups: two fixed dose groups (tirzepatide
0.5 mg and 5.0 mg) and two dose-titration
groups (tirzepatide 0.5/5/10/10 mg and 0.5/5/
10/15 mg) and a placebo group. The study had
4 weeks treatment followed by 4 weeks safety
follow-up. Baseline characteristics of study par-
ticipants were mean age 56.8 ± 6.9 years, 53%
male, 77% White, 13% Asian, 8% Black, BMI
31.2 ± 4.0 kg/m2 and HbA1c 8.4 ± 0.8% (all
values in mean ± SD). After 4 weeks treatment,
a statistically significant dose-dependent
reduction in HbA1c was observed in both titra-
tion groups compared to placebo. Fasting glu-
cose and fasting serum insulin were
significantly decreased in both titration groups
compared to placebo. All tirzepatide treatment
doses except 0.5 mg reduced the glucose
responses (glucose area under the curve [AUC])
during the oral glucose tolerance test (OGTT)
compared to placebo. Similarly, 7-point self-
monitoring of blood glucose demonstrated
reduction in postprandial glucose levels in a
dose-dependent manner. Similar to the HbA1c
reduction, a dose-dependent reduction in body
weight in tirzepatide groups compared to the
placebo group was observed. The 0.5/5/10/
10 mg and 0.5/5/10/15 mg groups achieved
2.39 kg and 2.95 kg weight loss respectively
[30].
A similar phase 1 placebo-controlled, ran-
domised study of tirzepatide was conducted in
48 Japanese people with T2DM. The treatment
arm of the Japanese study consisted of one fixed
(5 mg) dose group and two dose-titration groups
(2.5 mg for 2 weeks, 5 mg for 2 weeks and 10 mg
for 4 weeks; and 5 mg for 2 weeks, 10 mg for
4 weeks and 15 mg for 2 weeks). The study had a
treatment exposure of 8 weeks with a 4-weeks
safety follow-up. Baseline characteristics were
mean age 57.4 ± 8.8 years, 47% male, BMI
25.4 ± 3.2 kg/m2 and HbA1c 8.0 ± 0.8%. In
line with the proof-of-concept study, compared
to placebo there was a significant reduction in
HbA1c from baseline in all tirzepatide groups (-
1.62%, - 1.78%, - 2.05% in 5 mg, 10 mg,
15 mg tirzepatide respectively). Significant
reduction in body weight was also noted in all
three tirzepatide groups (weight loss of 1.9 kg,
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































IN PHASE 2 CLINICAL TRIALS
The phase 2 trial of tirzepatide was a 26-week,
placebo-controlled, double-blind, randomised
trial in 318 people with T2DM treated with
lifestyle intervention alone with or without
metformin monotherapy. The trial consisted of
two fixed dose (1 mg and 5 mg) tirzepatide
groups and two dose-titration groups (5 mg for
2 weeks and 10 mg for the remaining trial per-
iod; and 5 mg for 2 weeks, 10 mg for 4 weeks
and 15 mg for the remaining trial period). There
was also a dulaglutide 1.5 mg group and a pla-
cebo group. Baseline characteristics were mean
age 57 ± 9 years, 53% male, BMI 32.6 ± 5.9 kg/
m2, duration of diabetes 9 ± 6 years and HbA1c
8.1% ± 1%. Approximately 90% of subjects
received metformin at baseline and this con-
tinued throughout the trial period. In line with
the phase 1 clinical trials, the reduction in
HbA1c and fasting plasma glucose with tirze-
patide was dose dependent (HbA1c reduction
from baseline of 8% by 0.7%, 1.6%, 2.0% and
2.4% with 1 mg, 5 mg, 10 mg and 15 mg tirze-
patide doses, respectively). The 5 mg, 10 mg and
15 mg tirzepatide doses demonstrated a greater
reduction in HbA1c at 26 weeks, compared with
dulaglutide 1.5 mg. The proportion of patients
who achieved HbA1c targets of \7.0% and
\6.5% were higher in all tirzepatide groups
except 1 mg dose (90% and 82% achieved
HbA1c of\7% and\6.5%, respectively, in the
tirzepatide 10 mg group while 52% and 39%
achieved HabA1c of\ 7% and \6.5%, respec-
tively, in the dulaglutide group. Tirzepatide also
resulted in significant weight loss during the
trial period. Mean weight change from baseline
was - 0.9 kg, - 4.8 kg, - 8.7 kg and - 11.3 kg in
1 mg, 5 mg, 10 mg and 15 mg tirzepatide groups
compared to - 0.4 kg for placebo and - 2.7 kg
for dulaglutide. The proportion of patients who
achieved [5%, [10% and [ 15% weight loss
was 71%, 39% and 25%, respectively, in the
10 mg tirzepatide group; 62%, 38% and 22%,
respectively, in the 15 mg tirzepatide group;
22% and 9% of the dulaglutide group achieved
weight reduction of [5% and [10% respec-
tively [32].
Another phase 2 clinical trial with similar
objectives was designed to assess three dose-ti-
tration regimens of tirzepatide in people with
T2DM who received lifestyle intervention with
or without metformin therapy. The three dose
regimens were (1) the 12 mg group, (n = 29)
[4 mg for 4 weeks, 8 mg for 4 weeks and 12 mg
for 4 weeks]; (2) the 15 mg-1 group, (n = 28)
[2.5 mg for 2 weeks, 5 mg for 2 weeks, 10 mg for
4 weeks and 15 mg for 4 weeks]; and (3) the
15 mg-2 group, (n = 28) [2.5 mg for 4 weeks,
7.5 mg for 4 weeks and 15 mg for 4 weeks]. After
12 weeks of treatment, significant reductions in
HbA1c, fasting plasma glucose and body weight
were observed in all three treatment regimens,
compared to placebo. Mean HbA1c changes
from baseline ranged from - 1.7% to - 2.0%
and mean body weight changes ranged from -
5.3 kg to - 5.7 kg in the tirzepatide groups [33].
SAFETY AND TOLERABILITY
OF TIRZEPATIDE
Since tirzepatide is a dual GIP/GLP-1 agonist,
the side effect profile is comparable to that of a
GLP-1 receptor agonist. The most frequently
observed side effects were related to the gas-
trointestinal (GI) system and nausea, diarrhoea
and vomiting were the most common adverse
events. The incidence of GI adverse events was
23.1% for 1 mg, 32.7% for 5 mg, 51.0% for
10 mg and 66.0% for 15 mg, demonstrating a
dose-dependent behaviour (versus 42.6% for
dulaglutide and 9.8% for placebo). The second
most common adverse effect was reduced
appetite, the incidence ranging from 3.8% to
18.9% in tirzepatide-treated groups. Study drug
discontinuation due to adverse events was
greater with the higher dose of tirzepatide (25%
with the 15 mg group, 9.1% with the 10 mg
group and 5.1% with the 5 mg group); the dis-
continuation rate for dulaglutide was 11.1%
[32].
The titration-regimen trial also demon-
strated the dose-dependent incidence of GI
adverse events: 48.3%, 57.1% and 46.4% in the
tirzepatide 12 mg, 15 mg-1 and 15 mg-2 groups,
respectively, and 11.5% with placebo. Preva-
lence of study drug discontinuation due to
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adverse events was 3.4% (1 patient), 3.6% (1
patient), no patient and 3.8% (1 patient) in the
tirzepatide 12 mg, 15 mg-1, 15 mg-2 and pla-
cebo groups, respectively. These findings con-
trasted with those of the 26-week phase 2
clinical trial where a greater prevalence of study
drug discontinuation occurred in the higher
dose group. The study authors suggested that a
lower starting dose and small subsequent dose
increments were associated with lower inci-
dence of GI adverse events [33]. The severity of
GI adverse events in both trials was mild to
moderate.
With regard to hypoglycaemia, the incidence
of hypoglycaemia was low in both phase 2 trials
and comparable across the treatment groups. In
the 26-week trial, the prevalence of hypogly-
caemia was 9.8% and 7.5% in the 10 mg and
15 mg groups, respectively [32]. In the 12-week
trial, 6.9% in the 12 mg group, 17.9% in the
15 mg-1 group and 17.9% in the 15 mg-2 groups
reported hypoglycaemia [33]. There were no
reports of severe hypoglycaemia in either study.
Other adverse events included pancreatitis
(two patients in the tirzepatide 5 mg group),
cholecystitis (one patient in the tirzepatide
10 mg group and one in the dulaglutide 1.5 mg
group), injection site reactions (2–8% in tirze-
patide groups, 11.1% in the dulaglutide group
and 3.9% in the placebo group), hypersensitiv-
ity and antibody formation (3% in tirzepatide
groups, 9.8% in the placebo group and none in
the dulaglutide group) [32].
OVERVIEW OF THE SURPASS
CLINICAL TRIALS
The SURPASS clinical trial programme aimed to
assess the efficacy and safety of tirzepatide as a
treatment to improve glycaemic control in
people with T2DM (Table 3) [34–42]. The SUR-
PASS phase 3 clinical trials include six global,
two Japanese and one Asia–Pacific studies.
These trials include anti-hyperglycaemic ther-
apy-naı̈ve patients (patients treated with diet
and lifestyle alone) as well as patients on various
oral anti-hyperglycaemic agents (metformin,
sulfonylurea, pioglitazone, SGLT2 inhibitor
and/or insulin). Some studies are placebo-
controlled, and others have active comparators,
such as GLP-1 RAs (dulaglutide and semaglu-
tide), long-acting insulin analogues (glargine
and degludec) or short-acting insulin analogue
(lispro). The SURPASS trials are designed to
assess once weekly tirzepatide doses of 5 mg,
10 mg and 15 mg. Based on the results of the
phase 2 trials, a dose-escalation algorithm is
used in the phase 3 trials as follows: starting
dose at 2.5 mg weekly for initial 4 weeks, then
the dose increment of 2.5 mg every 4 weeks
until the maintenance dose of 5 mg, 10 mg or
15 mg is reached. Therefore, it takes 4 weeks to
reach the 5 mg dose, 12 weeks for the 10 mg
dose and 20 weeks for the 15 mg dose. The pri-
mary endpoint for each of the studies (except
SURPASS J-combo) is change in HbA1c from
baseline. The primary endpoint of the SURPASS
J combo is the number of participants with
more than one severe adverse event.
SURPASS-CVOT is a large phase 3, ran-
domised, double-blind, cardiovascular out-
comes trial for tirzepatide assessing both non-
inferiority and superiority of tirzepatide against
dulaglutide (1.5 mg weekly). The SURPASS-
CVOT will include 12,500 participants with
T2DM (aged 40 years, HbA1c between 7.5% and
10.5%, BMI C 25 kg/m2) and established
atherosclerotic cardiovascular disease from 30
countries. In addition to study drug, partici-
pants should continue to receive standard
medical care for diabetes which include con-
comitant oral glucose-lowering therapy and/ or
various insulin regimens. Participants who have
treatment with any GLP-1 RA or pramlintide in
3 months prior to screening visit and who dis-
continue a GLP-1 RA or pramlintide because of
intolerability are excluded from the study. Par-
ticipants with sever heart failure (NYHA class 4)
and those with end-stage renal disease or on
dialysis are excluded from the study. The use of
SGLT2 inhibitors at baseline is one of the
stratification factors for randomisation. Tirze-
patide is started at 2.5 mg weekly and to be
escalated to 15 mg weekly or to the highest
maintenance dose tolerated by the study par-
ticipant. The dose of dulaglutide is initiated and
maintained at 1.5 mg weekly. A sham dose
escalation of dulaglutide will be employed to















































































































































































































































































































































































































































































































































































































































































































































































































































































































































primary outcome measure is time to first
occurrence of death from cardiovascular (CV)
causes, non-fatal myocardial infarction (MI) or
non-fatal stroke (MACE-3). Secondary outcome
measures include time to all-cause mortality,
time to occurrence of each component of the
primary endpoint, time to first occurrence of
new or worsening nephropathy and change in
body weight, HbA1c, urine albumin to crea-
tinine ratio and lipid profile from baseline. The
study is event-driven and is expected to run for
approximately 54 months (randomisation up to
study completion).
CLINICAL SIGNIFICANCE
OF THE SURPASS CLINICAL TRIALS
Diabetes care has evolved over the last two
decades, shifting from a glucocentric approach
to multifactorial intervention with the aim of
minimising CV morbidity and mortality. Inter-
national guidelines recommend the choice of
anti-hyperglycaemic therapy based not only on
the degree of hyperglycaemia but also on the
presence or absence of CV disease, renal disease
and obesity. GLP-1 RAs and SGLT2 inhibitors
have gained popularity due to their clinical
efficacy and favourable CV outcomes. Despite
these developments, there are still unmet needs
for people living with diabetes, especially those
with obesity. Tirzepatide has demonstrated
greater HbA1c reduction (- 2.4% with 15 mg
tirzepatide) and superior weight loss (- 11.3 kg
with tirzepatide 15 mg) with comparable
adverse effects versus the GLP-1 RA dulaglutide
in phase 2 trials. Of note, semaglutide, currently
regarded as the most potent GLP-1 RA,
demonstrated 1.5–1.8% HbA1c reduction and
4.5–6.5 kg weight reduction [1]. It is not possi-
ble to compare the efficacy of tirzepatide and
semaglutide with available data from phase 2
trials; however, the SURPASS-2 trial will directly
compare the efficacy and safety of tirzepatide
versus semaglutide with the potential for supe-
riority of tirzepatide, particularly with respect to
weight reduction. Since the prevalence of dia-
besity is increasing, diabetes medications with
potent weight loss will be increasingly attractive
in modern diabetes care. Amongst available
GLP-1 RAs, liraglutide 3.0 mg daily subcuta-
neous injection (Saxenda) has approval for
chronic weight management in patients with
obesity or with a weight-related comorbidity
and a BMI C 27 kg/m2; however, for the man-
agement of T2DM, the approval licence remains
at the once daily dose of 1.8 mg [43]. In the
SCALE trial which compared liraglutide 3 mg
versus 1.8 mg versus placebo, there was a small
but significant reduction in weight and HbA1c
in the liraglutide 3 mg group compared to
liraglutide 1.8 mg group [44]. However, the
SCALE study was not designed to compare the
efficacy of liraglutide 3 mg versus 1.8 mg. In the
SCALE insulin trial, liraglutide 3 mg was asso-
ciated with a HbA1c reduction of 1.1% com-
pared to placebo (0.6%) [45]. Of interest, a
higher dose of dulaglutide for glucose lowering
was recently approved by the FDA [46] follow-
ing the AWARD-11 trial which demonstrated
HbA1c reduction of 1.9% and 1.7% and weight
reduction of 5 kg and 4.3 kg with dulaglutide
4.5 mg and 3 mg QW respectively [47].
Some SURPASS clinical trials include SGLT2
inhibitors as concomitant therapy (e.g. SUR-
PASS-3 and -4). SGLT2 inhibitors have a
favourable effect on weight and CVD outcomes.
It would be interesting to see the combined
effect of tirzepatide and SGLT2 inhibitors on
efficacy and CVD outcomes. Of interest, the
combined use of once weekly exenatide and
dapagliflozin resulted in superior HbA1c reduc-
tion and greater weight loss compared to the
exenatide group and the dapagliflozin group
[48]. Therefore, one can argue that tirzepatide
might not be solely responsible for favourable
results. None of the SURPASS trials are designed
to compare tirzepatide against SGLT2 inhibi-
tors. Further study comparing tirzepatide
against SGLT2 inhibitors would be of use in
clinical decision-making. Since the 2008 publi-
cation of FDA guidance on anti-hyperglycaemic
therapy, medications for diabetes should not
only be efficacious in reduction in HbA1c but
should also have favourable CV outcomes (at
least no negative CV impact). The SURPASS-
CVOT trial will provide long-term data on the




Tirzepatide has also been investigated for the
management of obesity in individuals without
T2DM. SURMOUNT-1, a phase 3, randomised,
double-blind, placebo-controlled trial, is ongo-
ing and plans to recruit 2400 participants with
obesity and comorbidity excluding T2DM
(those with BMI C 30 kg/m2, or C 27 kg/m2 and
previous diagnosis with at least one of the fol-
lowing comorbidities: hypertension, dyslipi-
daemia, obstructive sleep apnoea,
cardiovascular disease). The primary endpoints
are change in body weight from baseline and
percentage of participants achieving at least 5%
weight loss after 72 weeks [49]. SYNERGY-NASH
is a randomized, double-blind, placebo-con-
trolled phase 2 study comparing the efficacy
and safety of tirzepatide in patients with non-
alcoholic steatohepatitis (NASH) [50].
CONCLUSION
Tirzepatide, a dual GIP/GLP-1 receptor agonist,
is a new incretin-based therapy for type 2 dia-
betes. The degree of HbA1c reduction and
weight reduction observed in pre-clinical,
phase 1 and 2 clinical trials has not previously
been observed in diabetes clinical trials. The
comprehensive phase 3 SURPASS clinical trial
programme will confirm comparable efficacy,
safety and cardiovascular outcomes of tirzepa-
tide in the management of T2DM diabetes. The
SURPASS trials will also provide insight into
understanding of incretin hormones, particu-
larly the role of GIP in energy metabolism. The
SURPASS-1 trial is due to be completed in
October 2020 and results are eagerly awaited.
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